MacroGenics, Inc. MGNX

MGNX Company Overview

MacroGenics, Inc. is a U.S.-based biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of antibody-based therapeutics for the treatment of cancer. The company operates primarily within the biotechnology and oncology drug development industries, with a strategic emphasis on engineered monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs). Its core revenue sources have historically included collaboration agreements, milestone payments, licensing arrangements, and research funding from pharmaceutical partners, while the company continues advancing proprietary clinical-stage oncology programs.

The company’s pipeline is built around proprietary technology platforms including DART (Dual-Affinity Re-Targeting) and Fc optimization technologies designed to enhance immune system targeting and anti-tumor activity. MacroGenics has developed programs targeting HER2, B7-H3, CD123, and other oncology-related antigens. Founded in 2000 and headquartered in Rockville, Maryland, the company evolved from an antibody engineering research enterprise into a clinical-stage oncology developer with multiple strategic partnerships involving global pharmaceutical companies. Its positioning is supported by proprietary antibody engineering capabilities, in-house biologics expertise, and a portfolio of differentiated immuno-oncology candidates.